Oxford Biomedica inks LSA with new US biotech partner

Oxford Biomedica said on Wednesday that the new licence and supply agreement will grant its new partner a non-exclusive licence to utilise its LentiVector platform for use in the application of its lead programme - a cell-based therapy targeting a rare indication.

The London-listed group noted that under the terms of the five-year clinical supply arrangement, it will receive an undisclosed upfront payment, as well as additional payments related to the development and manufacturing of lentiviral vectors for use in clinical trials.

Oxford Biomedica will also receive certain development and regulatory milestone payments and an undisclosed royalty on the net sales of any drug product sold that utilises its LentiVector platform.

Chair and interim chief executive Dr Roch Doliveux said: "This partnership further demonstrates Oxford Biomedica's world leadership in the delivery of viral vectors for cell and gene therapies and the momentum we are building, with this being the fifth new or expanded customer partnership we have announced this year."

Reporting by Iain Gilbert at Sharecast.com